Facility details: 6,443 m² land parcel with 2,000 m² building constructed in 2023, includes administrative offices, labs with containment airlocks, temperature and humidity control, 256 solar panels, rainwater collection system
Rationale and Impact
Transitions Coris from tenant to owner-occupier of manufacturing facility
Eliminates intercompany rental payments, generating immediate net annual savings of €140,000 before depreciation
Consolidates Bilex accounts into Coris, simplifying financial statements
Future property-related expenses limited to bank interest on building loans (€2.11 million at 1.3%) and depreciation
Secures permanent infrastructure for global diagnostic pipeline operations
Regulatory Approvals
No governmental or regulatory approvals required for the acquisition
Transaction does not qualify as related party transaction
Promoter/promoter group has no interest in Bilex SRL
Management Commentary
Mr. Sébastien Goenen (CEO - Coris Bioconcept SRL): Acquisition provides long-term control over operating infrastructure, delivers recurring savings, and enables scaling of manufacturing capabilities
Mr. Dhirendra Dubey (Founder CEO - 3B BlackBio Dx Limited): Strengthens operational foundation of Coris, optimizes rental outflows, provides long-term certainty over critical operating asset
Company Background
3B BlackBio Dx Limited: Research-driven company developing IVD products under TRUPCR®, TRURAPID®, and TRUNGS® brands focused on oncology and infectious disease diagnostics
Coris Bioconcept SRL: Founded 1996, develops/manufactures IVD rapid test kits (lateral flow assays), ISO 13485 certified, distributes to over 60 countries